Remove

Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10534484			
Filing Date		2005-05-10			
First Named Inventor Mark		IS H KLEIN, ET AL			
Art Unit					
Examiner Name					
Attamen Dealest Numb		NI 024122			

		U.S. PATENTS					Helilove				
Examiner Initial*	Cite No	Patent Number	ber Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Releva		ines where es or Relev				
	1	5723950		1998-03-0	03	WEI, ET AL					
	2	6369781	B2	2002-04-0	09	HASHIMOTO,	ET AL				
	3	6369786	B1	2002-04-0	09	suzuki					
	4	5552677		1996-09-0	03	PAGONES					
If you wis	h to a	dd additional U.S. Pater	t citatio	n informat	tion pl	ease click the	Add button.		Add		
			U.S.P	ATENT A	PPLIC	CATION PUBL	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publicati Date	ion	Name of Patentee or Applicant of cited Document		Releva		ines where es or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi						d button.	=		_
	_			FOREIGI	N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or v		r Relevant	

U.S. PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Art Unit

Application Number		10534484			
Filing Date		2005-05-10			
First Named Inventor	Markus H KLEIN, ET AL				
Art Unit					
Examiner Name					
Attorney Docket Number		NL021122			

SEIKO EPSON CORP

Date Considered

	2	WO03098974		A1	2003-11-27	KPENV		
	3	JP10153984			1998-06-09	SONY CORP		
	4	EP1164567		A2	2001-12-19	SONY CORP		
	5	EP1164567		B1	2001-12-19	SONY CORP		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials* Cite Initials* Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Ţ5

2003-02-05

\*EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*See Kind Codes of USPTO Patient Documents at <a href="https://www.uspt.no.nu/mpt.no.nu/

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

1 See Kind Codes of USPTO Platest Documents at year-USPTO\_COMy or MEPP 90.104. 2 Enter diffice that issued the document, by the two-letter code (WIPO Assurded ST3.) 2 For Laplanese peater documents, the includation of the year of the neight on the Emperor many preceded the sent amountment of the pulled thousand. (Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark there if implications are attacked.

Examiner Signature

1 EP1282104

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10534484		
Filing Date		2005-05-10		
First Named Inventor Mark		IS H KLEIN, ET AL		
Art Unit				
Examiner Name				
Attornov Docket Numb	or	NI 021122		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on the agriculture.									
Signature	/Paul Im/	Date (YYYY-MM-DD)	2007-01-19						
Name/Print	Paul Im	Registration Number	50418						

This collection of information is required by 3T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CPR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed speciation from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. O. 8bx 1450, Alexandria, V.S. 2315-1450, D. ORY SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.